Advancement and prospects of tumor gene therapy

Zhang, Chao; Wang, Qing Tao; Li, He; Zhang, Zhen Zhu; Huang, Wen

doi:10.5732/cjc.010.10074

Cited by 21 publications

(17 citation statements)

References 67 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The primary measure for the treatment of esophageal carcinoma is surgery; however, recurrence is observed postoperatively in certain patients and affects the survival of these patients (25). The present study confirmed that patients with high expression of activin A preserved a lower cumulative survival rate and a higher cumulative recurrence rate compared with patients with low expression of activin A.…”

Section: Discussionsupporting

confidence: 82%

Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation

et al. 2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the expression of activin A in esophageal carcinoma and its association with tumor differentiation and metastasis. A total of 57 esophageal carcinoma patients and 36 controls were included in the current study. The mRNA and protein expression levels of activin A in esophageal tumors or normal esophageal tissues were determined by reverse transcription-quantitative polymerase chain reaction and immunohistochemical analysis. In addition, the association of activin A expression with esophageal carcinoma differentiation, metastasis and recurrence postoperatively was analyzed. The mRNA and protein expression levels of activin A in esophageal carcinoma were significantly higher compared with those in normal esophageal tissues (P<0.05). The expression of activin A was higher in poorly-/moderately-differentiated esophageal tumor tissues compared with that of well-differentiated or control tissues (P<0.05). Furthermore, the expression of activin A in poorly-differentiated esophageal tumor tissues was higher compared with that of moderately-differentiated tissues (P<0.05). A positive correlation was also observed between differentiation degree and activin A expression. The expression of activin A was higher in patients with lymph node metastasis compared with those without metastasis (P<0.05). The cumulative survival rate of patients with a high expression of activin A at 1, 2 and 3 years postoperatively was significantly decreased compared with that of patients with a lower expression of activin A (P<0.05); by contrast, the cumulative recurrence rate was significantly higher in patients with a lower activin A expression (P<0.05).In conclusion, abnormal expression of activin A was detected in esophageal tumor tissues, which was correlated with the tumor differentiation, metastasis, survival and recurrence. In conclusion, activin A may be used as an auxiliary index in the diagnosis and prognosis of clinical esophageal carcinoma.

show abstract

Section: Discussionsupporting

confidence: 82%

Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Recently, a wide variety of other gene therapies have been investigated in many malignancies, such as antiangiogenic, tumor-suppressor, cytokine-based and oxidative-based gene therapy (24). In addition, cell cycles regulate growth and differentiation.…”

Section: Discussionmentioning

confidence: 99%

Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: A potential strategy for cancer therapy

Zhang

Zhao

et al. 2012

International Journal of Molecular Medicine

View full text Add to dashboard Cite

In contrast to other enzymes, Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) has a broad substrate specificity and high catalytic rate when transferred in human cells. This makes it a promising therapeutic agent when administered together with several cytotoxic nucleoside analogs, such as gemcitabine 2',2'-difluoro-deoxycytidine (dFdC). Therefore, lentiviral vectors, which potentially allow stable long-term transgene expression, are good candidates for gene delivery vehicles. In the present study, we successfully developed a lentivirus-mediated transgene expression system of Dm-dNK under the control of hTERT promoter against the breast cancer cell line (Bcap37), the gastric cancer cell line (SGC7901) and the normal fibroblast cell line (WI-38). Moreover, we also analyzed its targeted cytotoxicity in vitro with treatment of the prodrug dFdC. Bcap37 tumor growth was inhibited in nude mice. Both cancer cell lines exhibited apparent cytotoxicity when infected with recombinant lentivirus constructs expressing Dm-dNK. In contrast, lentivirus-infected WI-38 cells exhibited less cytotoxicity. These data suggested that Dm-dNK was sensitive to dFdC, and it resulted in synergistic growth inhibition and apoptosis induction in vitro. In addition, Lenti-hTERT-dNK/dFdC also suppressed tumor growth in vivo. Our results suggest that the Lenti-hTERT-dNK/dFdC system is a safe and feasible treatment strategy in the development of suicide gene therapy.

show abstract

“…Biological therapy includes many methods such as target therapy, gene therapy and tumor vaccine, of which gene therapy is the most recent research topic (3). Evidence has shown that the occurrence and development of malignant tumor is closely related to gene alteration (3). Gene therapy may change the biological behavior of the tumor cells by correcting or repairing the malignant genes.…”

Section: Introductionmentioning

confidence: 99%

“…The members of this family play an important role in the occurrence and development of many tumors, therefore cytokine therapy is commonly used for tumor immunotherapy (3,4). In previous studies the focus was on the tumor itself, whereas increasingly investigations have focused on the tumor microenvironment.…”

Section: Introductionmentioning

confidence: 99%

Effect of IL-17 in the development of colon cancer in mice

et al. 2016

View full text Add to dashboard Cite

Cytokine therapy is commonly used for tumor immunotherapy. Although early studies focused directly on the tumor, current investigations are more attentive of the tumor microenvironment. Various immune cells and related cytokines in the tumor microenvironment play an important role in the occurrence and development of tumor. Interleukin (IL)-17 is the characteristic cytokine produced by Th17 cells. IL-17 has been associated with various immune responses. The results of previous studies showed that IL-17 can significantly reduce the size of transplanted tumors in tumor-bearing mice, albeit it has no effect on the survival time of mice. By investigating the effect of IL-17 in the number and distribution of lymphocyte infiltration in tumor tissues, the expression of cytokines and transcription factors associated with the subsets of CD4+T cells in tumor tissues, the distribution of subsets of spleen lymphocyte in tumor-bearing mice, a preliminary investigation of the possible antitumor mechanism of IL-17 was performed. In conclusion, the antitumor effect of IL-17 gene transfection in the colon cancer of mice may be associated with the mechanisms whereby IL-17 gene transfection can change the distribution of different subsets of spleen lymphocytes in mice. IL-17 gene transfection can increase the number of lymphocyte infiltration in tumor tissues. IL-17 gene transfection can promote the high expression of interferon-γ in tumor tissue, while reducing the expression of IL-10 and IL-13 factors, thus exerting an antitumor effect.

show abstract

Advancement and prospects of tumor gene therapy

Cited by 21 publications

References 67 publications

Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation

Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation

Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: A potential strategy for cancer therapy

Effect of IL-17 in the development of colon cancer in mice

Contact Info

Product

Resources

About